Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1997-03-03
2000-03-21
Budens, Robert D.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241871, A61K 3921
Patent
active
060399570
ABSTRACT:
The present invention relates to methods for producing recombinant HIV-1 envelope (env) oligomers for use as immunogens. When gp140 oligomeric glycoproteins were purified by sucrose velocity gradient sedimentation, and then used to immunize mice, the resulting humoral immune response was skewed toward the production of antibodies that recognize conformation-dependent epitopes on the HIV-1 env protein. Assays for HIV-1 infections are described, as well as immonogens for vaccinating against HIV-1 infection.
REFERENCES:
patent: 4725669 (1988-02-01), Essex et al.
Greene, Warner C.; AIDS and the Immune System; Life, Death and the Immune System; Scientific American, Sep. 1993; pp. 97-105.
Berman, Phillip W., et al.; Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160; NATURE, vol. 345; Jun. 14, 1990; pp. 622-625.
Berman, Phillip W., et al.; Expression and Immunogenicity of the Extracellular Domain of the Human Imminodeficiency Virus Type 1 Envelope Glycoprotein, gp160;Journal of Virology, 63:8; Aug. 1989, pp. 3489-3498.
Earl, et al. (1992) Multimeric CD4 binding exhibited by human and simian immunodeficiency virus envelope protein dimers. Journal of Virology 5610-5614.
Kieny, et al. (1988) Improved antigenicity of the HIV env protein by cleavage site removal. Protein Engineering 2(3):219-225.
Marasco, et al. Design, intracellular expression, and the activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody. Proc. Natl. Acad. Sci. 90:7889-7893.
Nakamura, et al. (1992) Monoclonal antibodies to the extracellular domain of HIV-1 IIIB gp160 that neutralize infectivity, block binding to CD4, and react with diverse isolates. Aids Research and Human Retroviruses 8(11).
Pasquali, et al. (1990) Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein. Aids Research and Human Retroviruses 6(9).
Steimer, et al. (1991) Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 254:105-108.
Seaver, S. (1994) Monoclonal antibodies in industry: more difficult than originally thought. Gen. Eng. News pp. 10, 21.
Earl et al, Proc. Natl. Acad. Sci. USA 87:648-652, Jan. 1990.
Earl et al., J. Virol. 65(1):31-41, Jan. 1991.
Galfre et al., Meth. Enzymol. 73:3-46, 1981.
Broder Christopher C.
Doms Robert W.
Earl Patricia L.
Moss Bernard
Budens Robert D.
United States of America, as represented by the Department of He
LandOfFree
Oligomeric HIV-1 envelope glycoproteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oligomeric HIV-1 envelope glycoproteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligomeric HIV-1 envelope glycoproteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-728118